John Pulice

Scientist at @foghorntx | PhD @BBS_Harvard in the @meyersonlab | Previously: @kadochlab @harvard ‘15 @TJHSST ‘11

[John Pulice @JohnPulice]

Excited to share the final published version of my PhD work out today in @MolecularCell! See below for a thread of updates for the final version from the preprint! 1/ https://t.co/yAG3Nix5sI

[John Pulice @JohnPulice]

@3rdMoment @Sturgeons_Law All PhD programs at Harvard are through FAS

[John Pulice @JohnPulice]

Nice new preprint on oncogene alterations in lung adenocarcinoma that reinforces what we and others have seen with mEGFR and NKX2-1! https://t.co/lh6TxLPUro

[John Pulice @JohnPulice]

Very curious to see how much of an outlier NKX2-1 is as more TFs and studies interrogate TF dosage in a mechanistic fashion!

[John Pulice @JohnPulice]

Cool new paper from the @WJGreenleaf lab on TF dosage by ATAC-seq! https://t.co/HG0N0bfv4d

[John Pulice @JohnPulice]

ICYMI: since the preprint, we added extensive interrogation of NKX2-1 dosage to the final manuscript by both titrated lentiviral overexpression and knockdown, with distinct effects of dosage in the two contexts (OE: linear/thresholded, KD: mostly linear). https://t.co/yAG3Nix5sI

[John Pulice @JohnPulice]

And if you're interested, check out our study on how NKX2-1 functions as a pioneer-like factor to drive lineage addiction through enhancer remodeling in lung adenocarcinoma! https://t.co/yAG3Nix5sI

[John Pulice @JohnPulice]

It's a big week for NKX2-1!
Check out new studies on (1) how HNF4a modulates NKX2-1-mediated lineage specification (https://t.co/uJ6w6BsbAe) and (2) how NKX2-1 drives neuroendocrine differentiation in prostate cancer (https://t.co/oSEVBagqHM)

[John Pulice @JohnPulice]

@jaybradner @Amgen Interesting to see the role of NKX2-1/TTF-1 here, we saw a role for it in EGFR persistence and speculated it might have a role for KRAS too!

Would be curious if NKX2-1 amplification status has any role here or if it’s just lineage state

https://t.co/yAG3Nix5sI

[Molecular Cell @MolecularCell]

Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma https://t.co/ojB8QZF6Te

[John Pulice @JohnPulice]

@Berkley_Gryder Thanks Berkley! Hope all is well!!

[Molecular Cell @MolecularCell]

Online Now: Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma https://t.co/VvfxDmb3nr

[John Pulice @JohnPulice]

@MolecularCell We've endeavored to make all the reagents and methods in this article as transparent and reproducible as possible. We deposited all plasmids (inc. pDONR cloning backbones and dTag OE destination vectors) on Addgene for easy use https://t.co/C9liTPasej 15/

[John Pulice @JohnPulice]

Excited to share the final published version of my PhD work out today in @MolecularCell! See below for a thread of updates for the final version from the preprint! 1/ https://t.co/yAG3Nix5sI

[John Pulice @JohnPulice]

@MolecularCell NKX2-1 is a complicated gene in cancer, with conflicting data for its role as a tumor suppressor and oncogene. Our data suggest NKX2-1 is a common oncogene and rare tumor suppressor in human LUAD, with it's TS role restricted to the rare IMA subtype 14/
https://t.co/ImIl0CUFuL